Abstract | BACKGROUND: METHOD: Points of agreement and majority opinions among 28 international experts in the field were identified by questionnaire. Agreement was defined as >80% concurrence, clear majority as >60% concurrence, and a majority or trend as >50% concurrence. RESULTS: Respondents agreed on the need for one term that reflects the inflammatory nature of the disease, but no agreement was reached on a specific term. Agreement included subdivision of patients with SpA into AS, psoriatic arthritis, inflammatory bowel disease associated arthritis, and undifferentiated spondyloarthritis/ spondyloarthropathy. A majority of experts defined active disease as fulfilling classification criteria for AS and/or a SpA, and disease activity measured by a Bath AS Disease Activity Index (BASDAI) score >4 determined by two patient visits during a two month period, but no maximum radiographic score. The majority of participants considered failure of treatment response to non-steroidal anti-inflammatory drugs ( NSAIDs) alone to be a prerequisite for active/severe AS, and 15/28 (54%) thought that NSAID treatment failure should be defined as lack of response to two or more NSAIDs. CONCLUSIONS: Respondents agreed that a two to five year study is the ethical method to demonstrate effects of anti-tumour necrosis factor alpha ( TNFalpha) therapy on radiographic progression of AS, and that inclusion criteria should include a certain level of disease activity (measured by BASDAI) and failure of certain treatments. After the efficacy of anti- TNFalpha therapy in AS and psoriatic arthritis is proved, respondents agreed that more studies will be needed to show efficacy for other SpA subsets.
|
Authors | J Braun, J Sieper |
Journal | Annals of the rheumatic diseases
(Ann Rheum Dis)
Vol. 61 Suppl 3
Pg. iii61-7
(Dec 2002)
ISSN: 0003-4967 [Print] England |
PMID | 12381512
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Tumor Necrosis Factor-alpha
- Sulfasalazine
- C-Reactive Protein
|
Topics |
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Antirheumatic Agents
(therapeutic use)
- C-Reactive Protein
(analysis)
- Consensus
- Forecasting
- Humans
- Magnetic Resonance Imaging
- Severity of Illness Index
- Spondylitis, Ankylosing
(classification, pathology)
- Sulfasalazine
(therapeutic use)
- Surveys and Questionnaires
- Terminology as Topic
- Treatment Failure
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|